BACKGROUND: The precise relationship between depression and cognitive decline in older adults is unclear. We investigated the influence of apolipoprotein E (APOE)-epsilon4 genotype in modulating the effect of depressive symptoms on cognitive decline. METHODS: Prospective cohort study of 1,487 cognitively high-functioning Chinese older adults. Depressive symptoms (Geriatric Depression Scale score >/=5) and Mini-Mental State Examination (MMSE) were assessed at baseline, and cognitive decline (at least 1-point drop in MMSE) at 1-2 years after baseline. RESULTS: There was no significant difference in cognitive decline between depressed (32.9%) and nondepressed (31.5%) participants in the whole sample or among non-APOE-epsilon4 carriers. Among APOE-epsilon4 carriers, depressed participants showed more cognitive decline (40.0%) than their nondepressed counterparts (28.6%), odds ratio = 2.89, 95% confidence interval: 1.03-8.12; p = .04, after controlling for age, gender, education, vascular risk factors/events, smoking, alcohol drinking, physical functioning, subjective memory complaint, length of follow-up, and baseline MMSE scores (p for interaction = .03). CONCLUSIONS: Our study suggests that the presence of the APOE-epsilon4 allele significantly enhanced the risk of cognitive decline associated with depressive symptoms. This finding should be independently replicated in future studies.
BACKGROUND: The precise relationship between depression and cognitive decline in older adults is unclear. We investigated the influence of apolipoprotein E (APOE)-epsilon4 genotype in modulating the effect of depressive symptoms on cognitive decline. METHODS: Prospective cohort study of 1,487 cognitively high-functioning Chinese older adults. Depressive symptoms (Geriatric Depression Scale score >/=5) and Mini-Mental State Examination (MMSE) were assessed at baseline, and cognitive decline (at least 1-point drop in MMSE) at 1-2 years after baseline. RESULTS: There was no significant difference in cognitive decline between depressed (32.9%) and nondepressed (31.5%) participants in the whole sample or among non-APOE-epsilon4 carriers. Among APOE-epsilon4 carriers, depressedparticipants showed more cognitive decline (40.0%) than their nondepressed counterparts (28.6%), odds ratio = 2.89, 95% confidence interval: 1.03-8.12; p = .04, after controlling for age, gender, education, vascular risk factors/events, smoking, alcohol drinking, physical functioning, subjective memory complaint, length of follow-up, and baseline MMSE scores (p for interaction = .03). CONCLUSIONS: Our study suggests that the presence of the APOE-epsilon4 allele significantly enhanced the risk of cognitive decline associated with depressive symptoms. This finding should be independently replicated in future studies.
Authors: M I Geerlings; R A Schoevers; A T Beekman; C Jonker; D J Deeg; B Schmand; H J Adèr; L M Bouter; W Van Tilburg Journal: Br J Psychiatry Date: 2000-06 Impact factor: 9.319
Authors: May A Beydoun; Marie T Fanelli-Kuczmarski; Melissa H Kitner-Triolo; Hind A Beydoun; Jay S Kaufman; Marc A Mason; Michele K Evans; Alan B Zonderman Journal: Psychosom Med Date: 2015-01 Impact factor: 4.312
Authors: Kumar B Rajan; Robert S Wilson; Kimberly A Skarupski; Carlos F Mendes de Leon; Denis A Evans Journal: Psychosom Med Date: 2014-01-16 Impact factor: 4.312
Authors: Ilan Dar-Nimrod; Benjamin P Chapman; John A Robbins; Anton Porsteinsson; Mark Mapstone; Paul R Duberstein Journal: Int J Geriatr Psychiatry Date: 2012-01-04 Impact factor: 3.485
Authors: Warren D Taylor; Brian Boyd; Rachel Turner; Douglas R McQuoid; Allison Ashley-Koch; James R MacFall; Ayman Saleh; Guy G Potter Journal: Brain Imaging Behav Date: 2017-02 Impact factor: 3.978
Authors: Zander Crook; Tom Booth; Simon R Cox; Janie Corley; Dominika Dykiert; Paul Redmond; Alison Pattie; Adele M Taylor; Sarah E Harris; John M Starr; Ian J Deary Journal: PLoS One Date: 2018-02-16 Impact factor: 3.240